The Centers of Disease Control and Prevention has launched an educational campaign aimed at informing health care providers about the health risks of diethylstilbestrol (DES) exposure.
Dr. Clara Hwang discusses study of precision medicine disparities in prostate cancer
Clara Hwang, MD, is the lead author of the study, “Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.”
Dr. Schwen on focal therapies for prostate cancer
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Information and Guidance on the Adoption of Surgical Innovation and Technology in Urogynecology
The aim of this document is to present a framework by which AUGS and its members can address the development of new technology and techniques, particularly in the surgical arena.
Speaking of Urology: Liquid biopsy in prostate cancer
In this episode, David M. Albala, MD, and Sanoj Punnen, MD, discuss precision medicine and the use of biomarker tests in prostate cancer screening and detection.
PSMA-PET leads imaging breakthroughs in prostate cancer paradigm
Daniel Spratt, MD, highlights the evolving paradigm of PET-based imaging agents in prostate cancer, with a focus on the impact of PSMA-PET imaging.
FDA requests additional data regarding cefepime-taniborbactam for cUTI
The FDA has issued a complete response letter regarding a new drug application for cefepime-taniborbactam for the treatment of patients with complicated urinary tract infection.
2 Commerce Drive Cranbury, NJ 08512